Unexpected patterns of Epstein-Barr virus transcription revealed by a High throughput PCR array for absolute quantification of viral mRNA

Virology

Volumn 474, Issue , 2015, Pages 117-130

  Tierney, Rosemary J ^a   Shannon Lowe, Claire D ^a   Fitzsimmons, Leah ^a   Bell, Andrew I ^a   Rowe, Martin ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Burkitt lymphoma; Epstein Barr virus; Herpesvirus; HHV4; Latency; Lytic replication; Transcription; Tumor virus; Viral gene expression

Indexed keywords

VIRUS MESSENGER RNA; BILF1 PROTEIN, EPSTEIN-BARR VIRUS; EBV-ENCODED NUCLEAR ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN; G PROTEIN COUPLED RECEPTOR; MESSENGER RNA; VIRUS PROTEIN; VIRUS RNA;

ARTICLE; B LYMPHOCYTE; BILF1 GENE; BILF2 GENE; BILF3 GENE; BURKITT LYMPHOMA CELL LINE; CONTROLLED STUDY; EBNA1 GENE; EBNA3A GENE; EBNA3B GENE; EBNA3C GENE; EPSTEIN BARR VIRUS; FLUIDIGM DYNAMIC ARRAY SYSTEM; GENE EXPRESSION; GENETIC ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LMP2 GENE; NONHUMAN; ONCOGENE; POLYMERASE CHAIN REACTION SYSTEM; PROMOTER REGION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; TUMOR BIOPSY; VIRION; VIRUS GENE; VIRUS INFECTIVITY; VIRUS LATENCY; VIRUS REPLICATION; VIRUS TRANSCRIPTION; BURKITT LYMPHOMA; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; PROCEDURES; TUMOR CELL LINE; VIROLOGY;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4;

B-LYMPHOCYTES; BURKITT LYMPHOMA; CELL LINE, TUMOR; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE EXPRESSION REGULATION, VIRAL; GENES, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, VIRAL; TRANSCRIPTION, GENETIC; VIRAL PROTEINS; VIRION; VIRUS LATENCY;

EID: 84910643215     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.10.030     Document Type: Article

References (69)

1. Ahmed W., Philip P.S., Tariq S., Khan G. Epstein-Barr virus-encoded small RNAs (EBERs) are present in fractions related to exosomes released by EBV-transformed cells. PLoS One 2014, 9:e99163.
2. Alfieri C., Birkenbach M., Kieff E. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology 1991, 181:595-608.
3. Allday M.J., Crawford D.H., Griffin B.E. Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. J. Gen. Virol. 1989, 70(Pt 7):1755-1764.
4. Altmann M., Hammerschmidt W. Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol. 2005, 3:e404.
5. Amoroso R., Fitzsimmons L., Thomas W.A., Kelly G.L., Rowe M., Bell A.I. Quantitative studies of Epstein-Barr virus-encoded microRNAs provide novel insights into their regulation. J. Virol. 2011, 85:996-1010.
6. Arrand J.R., Rymo L. Characterization of the major Epstein-Barr virus-specific RNA in Burkitt lymphoma-derived cells. J. Virol. 1982, 41:376-389.
7. Beisser P.S., Verzijl D., Gruijthuijsen Y.K., Beuken E., Smit M.J., Leurs R., Bruggeman C.A., Vink C. The Epstein-Barr virus BILF1 gene encodes a G protein-coupled receptor that inhibits phosphorylation of RNA-dependent protein kinase. J. Virol. 2005, 79:441-449.
8. Bell A.I., Groves K., Kelly G.L., Croom-Carter D., Hui E., Chan A.T., Rickinson A.B. Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J. Gen. Virol. 2006, 87:2885-2890.
9. Bergbauer M., Kalla M., Schmeinck A., Gobel C., Rothbauer U., Eck S., Benet-Pages A., Strom T.M., Hammerschmidt W. CpG-methylation regulates a class of Epstein-Barr virus promoters. PLoS Pathog. 2010, 6:e1001114.
10. Brooks L., Yao Q.Y., Rickinson A.B., Young L.S. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol. 1992, 66:2689-2697.
11. Caldwell R.G., Wilson J.B., Anderson S.J., Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998, 9:405-411.
12. Chau C.M., Deng Z., Kang H., Lieberman P.M. Cell cycle association of the retinoblastoma protein Rb and the histone demethylase LSD1 with the Epstein-Barr virus latency promoter Cp. J. Virol. 2008, 82:3428-3437.
13. Chen H., Smith P., Ambinder R.F., Hayward S.D. Expression of Epstein-Barr virus BamHI-A rightward transcripts in latently infected B cells from peripheral blood. Blood 1999, 93:3026-3032.
14. Concha M., Wang X., Cao S., Baddoo M., Fewell C., Lin Z., Hulme W., Hedges D., McBride J., Flemington E.K. Identification of new viral genes and transcript isoforms during Epstein-Barr virus reactivation using RNA-Seq. J. Virol. 2012, 86:1458-1467.
15. Croft N.P., Shannon-Lowe C., Bell A.I., Horst D., Kremmer E., Ressing M.E., Wiertz E.J., Middeldorp J.M., Rowe M., Rickinson A.B., Hislop A.D. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. PLoS Pathog. 2009, 5:e1000490.
16. Davenport M.G., Pagano J.S. Expression of EBNA-1 mRNA is regulated by cell cycle during Epstein-Barr virus type I latency. J. Virol. 1999, 73:3154-3161.
17. de Jesus O., Smith P.R., Spender L.C., Elgueta Karstegl C., Niller H.H., Huang D., Farrell P.J. Updated Epstein-Barr virus (EBV) DNA sequence and analysis of a promoter for the BART (CST, BARF0) RNAs of EBV. J. Gen. Virol. 2003, 84:1443-1450.
18. Deacon E.M., Pallesen G., Niedobitek G., Crocker J., Brooks L., Rickinson A.B., Young L.S. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J. Exp. Med. 1993, 177:339-349.
19. Dittmer D.P. Transcription profile of Kaposi's sarcoma-associated herpesvirus in primary Kaposi's sarcoma lesions as determined by real-time PCR arrays. Cancer Res. 2003, 63:2010-2015.
20. Dorner M., Zucol F., Berger C., Byland R., Melroe G.T., Bernasconi M., Speck R.F., Nadal D. Distinct ex vivo susceptibility of B-cell subsets to epstein-barr virus infection according to differentiation status and tissue origin. J. Virol. 2008, 82:4400-4412.
21. Fakhari F.D., Dittmer D.P. Charting latency transcripts in Kaposi's sarcoma-associated herpesvirus by whole-genome real-time quantitative PCR. J. Virol. 2002, 76:6213-6223.
22. Feederle R., Kost M., Baumann M., Janz A., Drouet E., Hammerschmidt W., Delecluse H.J. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 2000, 19:3080-3089.
23. Gilligan K., Sato H., Rajadurai P., Busson P., Young L., Rickinson A., Tursz T., Raab-Traub N. Novel transcription from the Epstein-Barr virus terminal EcoRI fragment, DIJhet, in a nasopharyngeal carcinoma. J. Virol. 1990, 64:4948-4956.
24. Gregory C.D., Rowe M., Rickinson A.B. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt lymphoma cell line. J. Gen. Virol. 1990, 71:1481-1495.
25. Habeshaw G., Yao Q.Y., Bell A.I., Morton D., Rickinson A.B. Epstein-Barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains prevalent in different geographic areas. J. Virol. 1999, 73:965-975.
26. Jochum S., Ruiss R., Moosmann A., Hammerschmidt W., Zeidler R. RNAs in Epstein-Barr virions control early steps of infection. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E1396-1404.
27. Kalla M., Gobel C., Hammerschmidt W. The lytic phase of epstein-barr virus requires a viral genome with 5-methylcytosine residues in CpG sites. J. Virol. 2012, 86:447-458.
28. Kalla M., Hammerschmidt W. Human B cells on their route to latent infection-early but transient expression of lytic genes of Epstein-Barr virus. Eur. J. Cell Biol. 2012, 91:65-69.
29. Kalla M., Schmeinck A., Bergbauer M., Pich D., Hammerschmidt W. AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:850-855.
30. Kanda T., Yajima M., Ahsan N., Tanaka M., Takada K. Production of high-titer Epstein-Barr virus recombinants derived from Akata cells by using a bacterial artificial chromosome system. J. Virol. 2004, 78:7004-7015.
31. Kelly G., Bell A., Rickinson A. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat. Med. 2002, 8:1098-1104.
32. Kelly G.L., Long H.M., Stylianou J., Thomas W.A., Leese A., Bell A.I., Bornkamm G.W., Mautner J., Rickinson A.B., Rowe M. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in Burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog. 2009, 5:e1000341.
33. Kelly G.L., Milner A.E., Baldwin G.S., Bell A.I., Rickinson A.B. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:14935-14940.
34. Kelly G.L., Milner A.E., Tierney R.J., Croom-Carter D.S., Altmann M., Hammerschmidt W., Bell A.I., Rickinson A.B. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis. J. Virol. 2005, 79:10709-10717.
35. Kieff E., Rickinson A.B. Epstein-Barr Virus and its Replication, Fields Virology 2007, 2603-2654. Lippincott-Williams and Wilkins Publishers, Philadelphia, PA.
36. Kubota N., Wada K., Ito Y., Shimoyama Y., Nakamura S., Nishiyama Y., Kimura H. One-step multiplex real-time PCR assay to analyse the latency patterns of Epstein-Barr virus infection. J. Virol. Methods 2008, 147:26-36.
37. Kurokawa M., Ghosh S.K., Ramos J.C., Mian A.M., Toomey N.L., Cabral L., Whitby D., Barber G.N., Dittmer D.P., Harrington W.J. Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood 2005, 106:235-240.
38. Lerner M.R., Andrews N.C., Miller G., Steitz J.A. Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proc. Natl. Acad. Sci. U.S.A. 1981, 78:805-809.
39. Lin Z., Xu G., Deng N., Taylor C., Zhu D., Flemington E.K. Quantitative and qualitative RNA-Seq-based evaluation of Epstein-Barr virus transcription in type I latency Burkitt's lymphoma cells. J. Virol. 2010, 84:13053-13058.
40. Lyngaa R., Norregaard K., Kristensen M., Kubale V., Rosenkilde M.M., Kledal T.N. Cell transformation mediated by the Epstein-Barr virus G protein-coupled receptor BILF1 is dependent on constitutive signaling. Oncogene 2010, 29:4388-4398.
41. Mancao C., Hammerschmidt W. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 2007, 110:3715-3721.
42. Niedobitek G., Agathanggelou A., Rowe M., Jones E.L., Jones D.B., Turyaguma P., Oryema J., Wright D.H., Young L.S. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood 1995, 86:659-665.
43. Nonkwelo C., Skinner J., Bell A., Rickinson A., Sample J. Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J. Virol. 1996, 70:623-627.
44. Paulsen S.J., Rosenkilde M.M., Eugen-Olsen J., Kledal T.N. Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor. J. Virol. 2005, 79:536-546.
45. Pegtel D.M., Cosmopoulos K., Thorley-Lawson D.A., van Eijndhoven M.A., Hopmans E.S., Lindenberg J.L., de Gruijl T.D., Wurdinger T., Middeldorp J.M. Functional delivery of viral miRNAs via exosomes. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:6328-6333.
46. Pfeffer S., Zavolan M., Grasser F.A., Chien M., Russo J.J., Ju J., John B., Enright A.J., Marks D., Sander C., Tuschl T. Identification of virus-encoded microRNAs. Science 2004, 304:734-736.
47. Ramasubramanyan S., Osborn K., Flower K., Sinclair A.J. Dynamic chromatin environment of key lytic cycle regulatory regions of the Epstein-Barr virus genome. J. Virol. 2012, 86:1809-1819.
48. Ressing M.E., Keating S.E., van Leeuwen D., Koppers-Lalic D., Pappworth I.Y., Wiertz E.J., Rowe M. Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection. J. Immunol. 2005, 174:6829-6838.
49. Rickinson A.B., Kieff E. Epstein-Barr virus. Fields Virology 2007, 2655-2700. Lippincott, Williams & Wilkins, Philadelphia, PA. fifth ed. D.M. Knipe, P.M. Howley (Eds.).
50. Rowe M., Lear A.L., Croom-Carter D., Davies A.H., Rickinson A.B. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J. Virol. 1992, 66:122-131.
51. Sadler R.H., Raab-Traub N. Structural analyses of the Epstein-Barr virus BamHI A transcripts. J. Virol. 1995, 69:1132-1141.
52. Schaefer B.C., Strominger J.L., Speck S.H. The Epstein-Barr virus BamHI F promoter is an early lytic promoter: lack of correlation with EBNA 1 gene transcription in group 1 Burkitt's lymphoma cell lines. J. Virol. 1995, 69:5039-5047.
53. Schaefer B.C., Strominger J.L., Speck S.H. Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:10565-10569.
54. Schwanhausser B., Busse D., Li N., Dittmar G., Schuchhardt J., Wolf J., Chen W., Selbach M. Global quantification of mammalian gene expression control. Nature 2011, 473:337-342.
55. Shannon-Lowe C., Adland E., Bell A.I., Delecluse H.J., Rickinson A.B., Rowe M. Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. J. Virol. 2009, 83:7749-7760.
56. Shannon-Lowe C., Baldwin G., Feederle R., Bell A., Rickinson A., Delecluse H.J. Epstein-Barr virus-induced B-cell transformation: quantitating events from virus binding to cell outgrowth. J. Gen. Virol. 2005, 86:3009-3019.
57. Spurgeon S.L., Jones R.C., Ramakrishnan R. High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. PLoS One 2008, 3:e1662.
58. Takada K., Ono Y. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J. Virol. 1989, 63:445-449.
59. Tao Q., Robertson K.D., Manns A., Hildesheim A., Ambinder R.F. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood 1998, 91:1373-1381.
60. Thorley-Lawson D.A., Hawkins J.B., Tracy S.I., Shapiro M. The pathogenesis of Epstein-Barr virus persistent infection. Curr. Opin. Virol. 2013, 3:227-232.
61. Tierney R.J., Kao K.Y., Nagra J.K., Rickinson A.B. Epstein-Barr virus BamHI W repeat number limits EBNA2/EBNA-LP coexpression in newly infected B cells and the efficiency of B-cell transformation: a rationale for the multiple W repeats in wild-type virus strains. J. Virol. 2011, 85:12362-12375.
62. Touitou R., O'Nions J., Heaney J., Allday M.J. Epstein-Barr virus EBNA3 proteins bind to the C8/alpha7 subunit of the 20S proteasome and are degraded by 20S proteasomes in vitro, but are very stable in latently infected B cells. J. Gen. Virol. 2005, 86:1269-1277.
63. Wang F.Z., Roy D., Gershburg E., Whitehurst C.B., Dittmer D.P., Pagano J.S. Maribavir inhibits Epstein-Barr virus transcription in addition to viral DNA replication. J. Virol. 2009, 83:12108-12117.
64. Wen W., Iwakiri D., Yamamoto K., Maruo S., Kanda T., Takada K. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes. J. Virol. 2007, 81:1037-1042.
65. Whitehurst C.B., Sanders M.K., Law M., Wang F.Z., Xiong J., Dittmer D.P., Pagano J.S. Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase. J. Virol. 2013, 87:5311-5315.
66. Woisetschlaeger M., Yandava C.N., Furmanski L.A., Strominger J.L., Speck S.H. Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:1725-1729.
67. Xue S.A., Labrecque L.G., Lu Q.L., Ong S.K., Lampert I.A., Kazembe P., Molyneux E., Broadhead R.L., Borgstein E., Griffin B.E. Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi. Int. J. Cancer 2002, 99:635-643.
68. Yandava C.N., Speck S.H. Characterization of the deletion and rearrangement in the BamHI C region of the X50-7 Epstein-Barr virus genome, a mutant viral strain which exhibits constitutive BamHI W promoter activity. J. Virol. 1992, 66:5646-5650.
69. Yuan J., Cahir-McFarland E., Zhao B., Kieff E. Virus and cell RNAs expressed during Epstein-Barr virus replication. J. Virol. 2006, 80:2548-2565.